Refereed journal article or data article (A1)
Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT
List of Authors: Karagiannis Vasileios, Wichmann Viktor, Saarinen Juha, Eigeliene Natalja, Andersen Heidi, Jekunen Antti
Publisher: BMC
Publication year: 2022
Journal: Radiation Oncology
Journal name in source: RADIATION ONCOLOGY
Journal acronym: RADIAT ONCOL
Article number: 19
Volume number: 17
Number of pages: 9
DOI: http://dx.doi.org/10.1186/s13014-022-01989-5
URL: https://doi.org/10.1186/s13014-022-01989-5
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/174785218
Background: Prostate cancer is the most common cancer among men, and its diagnosis and treatment are improving. Our study evaluated how PSMA-PET/CT prior to treatment planning might improve the optimal management of prostate cancer radiotherapy.
Methods: This retrospective pilot study included 43 prostate cancer (PCa) patients referred to our radiation oncologist department, from the urology department, for radiation therapy. 18F-PSMA-PET/CT was ordered by the radiation oncologists mainly due to the lack of resent image staging. The patients were divided into three different groups according to their initially planned treatments: radical radiation therapy (RT) (newly diagnosed PCa patients), salvage RT (patients with biochemical recurrence after radical prostatectomy), or oligometastatic RT (oligometastatic PCa patients with good response after systemic treatment).
Results: Following PSMA-PET/CT, the initially planned RT was changed for 60.5% of the patients due to new findings (metastases and/or recurrent disease). The final treatment choice was effected by PSMA-PET/CT outcome in 60.5% (26/43) of the patients, and in 50% (16/32) of patients, the radiation treatment plan changed following PSMA-PET/CT. Only 39.5% (17/43) of the patients who underwent PSMA-PET/CT were treated according to their initial treatment plans.
Conclusions: Our results indicate that PSMA-PET/CT impacts treatment decisions and the selection of RT as well as adjuvant treatment protocols in the management of prostate cancer.
Downloadable publication This is an electronic reprint of the original article. |